One Test - Three Clinical Answers for Breast Cancer Patients
EndoPredict is the ONLY predictive and prognostic test to answer three critical clinical questions…
… to optimize treatment for N0/N+ breast cancer patients of each age
Chemotherapy
Treatment
Confidence
Chemotherapy
Treatment
Confidence
EndoPredict is a gene expression assay
for patients with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) early stage breast cancer who are lymph node negative or positive (N0, N1, micrometastases).
This second generation test combines a 12-Gene Molecular Score with tumor size and nodal status to provide more prognostic power than any other test.
EndoPredict Provides Superior Prognostic Performance - Results You Can Trust
• Identifies the most women with breast cancer at true low risk in head-to-head comparison with competitors.
• Leads to a significant impact on therapy decision to give the right therapy to the right patient.
• Predicts individualized absolute chemotherapy benefit for confident treatment decisions.
• Provides 10 year and up to 15 year risk prediction for long term confidence.
• Offers definitive risk classification in low or high risk.
• Delivers fast result by local testing.
EndoPredict provides an individualized test result for each patient that allows for a quick, easy to understand risk assessment that can help deciding whether to safely forego chemotherapy or extended endocrine therapy.
Filipits M. et al.: A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors. Clin Cancer Res. 2011; 17(18):6012-6020
Sestak I. et al.: Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. Breast Cancer Res Treat. 2019; 176:377-386
Filipits M. et al.: Prediction of Distant Recurrence using EndoPredict among Women with ER+, HER2- Node- Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only. Clin Cancer Res. 2019;25:3865-3872
Buus et al. Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy. J Natl Cancer Inst. 2016 Jul 10; 108(11)
Sestak I. et al.: Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer. A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2018; 4(4):545-553
Muller B.M. et al.: The EndoPredict Gene-Expression Assay in Clinical Practice – Performance and Impact on Clinical Decisions. PloSONE. 2013; 8(6): e68252
Penault-Llorca et al.: A prospective multicenter non-randomized trial evaluating the effect of EndoPredict® (EPclin®) clinicogenomic test on treatment decision making among patients with intermediate clinical risk. SABCS 2016
Ettl J. et al.: Decision Impact and feasibility of different ASCO-recommended biomarkers in early breast cancer: Prospective comparison of molecular marker EndoPredict and protein marker UPA/PAI-1. PLoSONE. 2017; 12(9): e0183917
Physicians
I am a physician looking to find critical answers about my patients’ cancer to provide peace of mind.
Patients
I am a patient looking for answers that will help guide cancer treatment decisions and provide peace of mind.
Pathologists
I am searching for an EndoPredict provider or I am interested in running EndoPredict in my laboratory.
